LB Investment

Activity from announced rounds

Activity in this selectionUnited States · Oct 21, 2026 · Jul 24, 2026

LB Investment is the Korean investment firm identified as lead by ImpriMed and associated with partner Kiho Park.

Recorded funding activity

ImpriMed tests live cancer cells against medicines and combines the results with clinical data. Point2 develops interconnect hardware, while CarbonSix develops robotic intelligence for manufacturing. These companies retain their distinct products and participant roles.

Sources
Rounds participated in
2
Confirmed lead rounds
1
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$144.5M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Series B1

By primary sector

Climate tech1
Hardware1

By country

United States2

Rounds

2 in this selection
Pascal

Solid-refrigerant cooling systems that combine porous materials and carbon dioxide to move heat.

$8.5MSeed extension
Lead
Point2 Technology

Develops RF-based interconnect technology for AI data-center and automotive networking

$136MSeries B
Role not disclosed